Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GS-9137- A Novel HIV-1 Integrase Inhibitor · 1 trial · 3 indications
| Name | Type | Description |
|---|---|---|
| GS-9137 - A Novel HIV-1 Integrase Inhibitor | DRUG | - |
Inclusion Criteria: * HIV RNA greater than or equal to 1000 c/mL. * Failed/Failing protease inhibitor based antiretroviral therapy. * Stable antiretroviral therapy for greater than or equal to 30 days prior to screening. * Negative Serum Pregnancy Test. * GFR by Cockcroft Gault greater than or equa...
GS-9137 is an investigational small molecule being developed for the treatment of HIV, including HIV-1 and human immunodeficiency virus infections. It is currently in Phase 2 clinical development and is not yet approved by regulatory authorities.
GS-9137 is a novel HIV-1 integrase inhibitor. It works by targeting the integrase enzyme, which is essential for HIV replication, thereby potentially blocking the virus from integrating into host cells.
GS-9137 is being developed by Gilead Sciences, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol GILD. The company is conducting clinical trials to evaluate the drug's safety and efficacy in HIV patients.
GS-9137 is currently in Phase 2 clinical development. It is an investigational drug, meaning it has not yet been approved by the FDA or other regulatory bodies for commercial use.
GS-9137 has one completed Phase 2 clinical trial, identified as NCT00298350. This study evaluated ritonavir-boosted GS-9137 versus ritonavir-boosted protease inhibitors in combination with background antiretroviral therapy in 278 participants with HIV.
GS-9137 is also known as elvitegravir, an HIV-1 integrase inhibitor. This alternative name is used in clinical and research contexts to refer to the same investigational drug developed by Gilead Sciences.